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In a 1532 publication, Sir Thomas More—an English lawyer
and social philosopher—likened one’s ability to find a line
in St. Austin’s writing to finding a needle in a meadow—later
interpreted as a “needle in the haystack.”1 The isolation ex-
perienced by patients with rare diseases can often make them
feel like lost needles in the meadow of our large complex
health care systems. As of 2018, there were 327.2 million
people with the potential to have data stored across 5534
registered hospitals in the United States alone along with
over 1100 different electronic health record vendors.2
The frustration experienced by those eager to connect in-
dividuals with rare diseases to clinical care and re-
search opportunities is magnified by the fact that our
electronic medical record systems at times fall short of
“meaningful use” and do many things to the exception of
connecting to other systems and providing efficient com-
munication. The effect that this complicated meadow
has on clinical care has been well described, but the bar-
riers that this poses to patient recruitment into clinical
and other research trials are less addressed in published
literature.
Recruitment of patients for clinical trials is an area ready
for innovation. At a time when there is measurable interest
and support from industry sponsoring clinical trials in the
glomerular disease space, connecting the right patients to
the right trials as efficiently as possible is of great import.
Harnessing data from electronic health records (EHRs) to
streamline and personalize clinical trial recruitment using
computable phenotypes has the potential to decrease the
time and money associated with clinical trial setup. Indeed,
global spending on clinical trial technology and services is
expected to reach $69 billion per year by 2025.3 EHR-powered
analytic tools are already commercialized for the purposes
of protocol feasibility, cohort analysis, and study site
identification.
Computable phenotypes represent the building blocks
with which we can interact with “big” health care data for
the purposes of advancing patient care and clinical outcomes.
Comparative effectiveness research, quality improvement
initiatives, clinical trial recruitment, or even the possibility
of conducting high-quality, multicenter, clinical trials within
an EHR also exist. Operationalizing these activities using
EHR data depends on having validated tools to define pa-
tient characteristics, diseases, or clinical events of interest.
Numerous computable phenotypes have been developed,
validated, and made available publicly, including for CKD,
treatment resistant hypertension, type 2 diabetes, steroid-
induced osteonecrosis, and many others.4 Most recently,
Norton et al.5 published an article in the September 2019
issue of CJASN detailing their development of a pragmatic
computable phenotype to identify patients likely to have
CKD.
In this issue of JASN, Denberg et al.6 report their newly
developed computable phenotype for glomerular disease
using a rule-based algorithm derived from 561 outpatient
nephrology clinic encounters at the Children’s Hospital of
Philadelphia. Multiple data elements were evaluated for
use in the computable phenotype, including demographic
information, diagnostic codes, laboratory data (urine pro-
tein to creatinine ratio), medication prescriptions (i.e., an-
giotensin-converting enzyme inhibitor), and kidney biopsy
reports. The authors show that a phenotype using a combina-
tion of health care encounters, diagnosis codes, and kidney
biopsy procedure codes could be used to identify patients
with glomerular disease who have a positive predictive value
of 92% and a negative predictive value of 100%. The com-
putable phenotype was then validated using structured
chart reviews at eight additional institutions within the
PEDSnet collaborative (a large, national community of hos-
pitals and healthcare organizations, researchers and clini-
cians, and patients and families), totally 800 patients with
glomerular disease and 798 patients with nonglomerular
disease.6
Several strengths of the study should be noted, includ-
ing its rigorous development and validation across multi-
ple collaborating children’s hospitals. The authors report
that the majority of urine protein assessments were on the
basis of urine dipstick measurements, and they were ex-
cluded due to concerns that dipsticks might not be able to
discriminate glomerular from nonglomerular proteinuria.
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Future work might test this hypothesis given the poten-
tial application of this phenotype to identify clinically sig-
nificant subgroups of patients with glomerular disease or
particular disease states, such as disease remission or
relapse.
The recent boom of tools to query EHRs is a welcome
development given the many potential applications, such
as facilitating quality initiatives in our growing era of
value-based care medicine and efficiently identifying
outcomes or adverse events in clinical trials/studies to
name a few. Any new technology involving protected
health information requires a delicate balance between pa-
tient privacy and data privacy. With the enormity of data
points and complexity of the phenotypes, collaboration
between physicians, computer scientists, and informati-
cians is paramount. Lastly, clinical phenotypes can change
over time and are dynamic, and therefore, the methods
to update these computable phenotypes must also be dy-
namic and maintain the capability of being validated
efficiently.
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